Resmed – Strong Earnings

ResMed is under Algo Engine buy conditions and is a current holding in our ASX model portfolio.

Resmed reported better than expected 1Q21 earnings with group revenue up 10% and NPAT up 37% on the same time last year.

You’re not a member!  Trial today

At 35x PE Resmed remains expensive and will need to maintain double-digit earnings growth to sustain the current valuation.

Buy on future share price weakness.

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.